Abstract:Ethnopharmacological relevance Berberine (BBR) is the main active component from Coptidis rhizome , a well-known Chinese herbal medicine used for metabolic diseases, especially diabetes for thousands of years. BBR has been reported to cure various metabolic disorders, such as nonalcoholic fatty liver disease (NAFLD). However, the direct proteomic targets and underlying molecular mechanism of BBR against NAFLD remain less understood. Aim of the study To investigate the direct target and corresponding molecular mechanism of BBR on NAFLD is the aim of the current study. Materials and methods High-fat diet (HFD)-fed mice and oleic acid (OA) stimulated HepG2 cells were utilized to verify the beneficial impacts of BBR on glycolipid metabolism profiles. The click chemistry in proteomics, DARTS, CETSA, SPR and fluorescence co-localization analysis were conducted to identify the targets of BBR for NAFLD. RNA-seq and shRNA/siRNA were used to investigate the downstream pathways of the target. Results BBR improved hepatic steatosis, ameliorated insulin resistance, and reduced TG levels in the NAFLD models. Importantly, Aldo-keto reductase 1B10 (AKR1B10) was first proved as the target of BBR for NAFLD. The gene expression of AKR1B10 increased significantly in the NAFLD patients' liver tissue. We further demonstrated that HFD and OA increased AKR1B10 expression in the C57BL/6 mice's liver and HepG2 cells, respectively, whereas BBR decreased the expression and activities of AKR1B10. Moreover, the knockdown of AKR1B10 by applying shRNA/siRNA profoundly impacted the beneficial effects on the pathogenesis of NAFLD by BBR. Meanwhile, the changes in various proteins (ACC1, CPT-1, GLUT2, etc .) are responsible for hepatic lipogenesis, fatty acid oxidation, glucose uptake, etc . by BBR were reversed by the knockdown of AKR1B10. Additionally, RNA-seq was used to identify the downstream pathway of AKR1B10 by examining the gene expression of liver tissues from HFD-fed mice. Our findings revealed that BBR markedly increased the protein levels of PPARα while downregulating the expression of PPARγ. However, various proteins of PPAR signaling pathways remained unaffected post the knockdown of AKR1B10. Conclusions BBR alleviated NAFLD via mediating PPAR signaling pathways through targeting AKR1B10. This study proved that AKR1B10 is a novel target of BBR for NAFLD treatment and helps to find new targets for the treatment of NAFLD by using active natural compounds isolated from traditional herbal medicines as the probe.

Berberine prevents NAFLD and HCC by modulating metabolic disorders

Berberine Ameliorates Nonalcoholic Fatty Liver Disease by A Global Modulation of Hepatic Mrna and Lncrna Expression Profiles

The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease

Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways

Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota

Berberine alleviates fructose-induced hepatic injury via ADK/AMPK/Nrf2 pathway: A novel insight

A Comprehensive Insight into the Effect of Berberine on Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review

Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies

Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity

Berberine Attenuates Nonalcoholic Hepatic Steatosis Through the AMPK-SREBP-1c-SCD1 Pathway.

Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway

Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD

Berberine Ameliorates High-fat-induced Insulin Resistance in HepG2 Cells by Modulating PPARs Signaling Pathway

Protective Effects of Berberine on Nonalcoholic Fatty Liver Disease in db/db Mice via AMPK/SIRT1 Pathway Activation

Berberine Alleviates Nonalcoholic Fatty Liver Induced by a High-Fat Diet in Mice by Activating SIRT3.

Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats

Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells

Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases

Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver

Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review